First of Three Patents Issued

February 17, 2020

Over the past two years, MSA has worked closely with Bryn Pharma to develop a new system for delivering epinephrine to treat patients suffering from severe allergic reactions. This new approach will include a nasal delivery system containing a new formulation of epinephrine. This novel formulation is designed for nasal delivery and was a subject of a series of pre-clinical studies that provided the basis for three patent applications. The first of the patents have been issued, with the remaining two still pending.  Named on the patent are MSA Principals, Kenneth Dretchen, Ph.D., and Michael Mesa, along with MSA associate Matt Robben Ph.D.

MSA News

Progress During the Pandemic

August 31, 2020 – Our surviving the Covid-19 experience has been an example of what having a great team can…

Read More

MSA and COVID-19

Frederick, MD July 17, 2020 – MSA has decided to delay the full-time return to our Frederick offices indefinitely.  Unfortunately,…

Read More

Mesa Science Associates and Bryn Pharma Publish Final of Three Pre-Clinical Studies of a New Approach to Treating Anaphylaxis

The third in a series of studies measured cerebrospinal fluid epinephrine pharmacokinetics, nasal mucosa effects, plasma epinephrine pharmacokinetics, and cardiovascular…

Read More